{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:36:36Z","timestamp":1794562596426,"version":"4.9.1"},"reference-count":104,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      One hundred eighty-five adults with severe TRD (average of 8.1 antidepressant trials plus electroconvulsive therapy in 63% without beneficial outcome) received oral esketamine treatment twice-weekly for 6\u2009weeks with individually titrated doses ranging from 0.5 to 3\u2009mg\/kg. Outcome measures included change from baseline to week 6 on the Hamilton Depression Rating Scale (HDRS\n                      <jats:sub>17<\/jats:sub>\n                      ), Minimal Clinically Important Difference (MCID), response, remission, self-reported symptom improvement, functioning, and side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Oral esketamine treatment improved depressive symptom severity on the HDRS\n                      <jats:sub>17<\/jats:sub>\n                      from 21.2 to 15.8 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). MCID, response, and remission rates were 47.1%, 26.8% and 15.6% respectively. In 45.9% of participants, treatment was continued after 6\u2009weeks to maintain initial positive effects. Side effects were reported frequently but were overall well tolerated. The drop-out rate was 7.6%. We found no significant adverse effects associated with urinary tract or cognition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Repeated treatment with oral esketamine is effective in improving depressive symptom severity in highly treatment-resistant depressive patients. It is safe, well tolerated, and patient-friendly. Considering the level of treatment resistance, outcomes were in the range of studies investigating other routes of (es)ketamine administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251332831","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T01:18:32Z","timestamp":1745630312000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-4804","authenticated-orcid":false,"given":"Jolien KE","family":"Veraart","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"Department of Psychiatry, PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-262X","authenticated-orcid":false,"given":"Sanne Y","family":"Smith-Apeldoorn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"van der Meij","sequence":"additional","affiliation":[{"name":"Depression Expertise Center, Pro Persona Mental Health Care, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Spijker","sequence":"additional","affiliation":[{"name":"Depression Expertise Center, Pro Persona Mental Health Care, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Schoevers","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"Behavioural Science Institute, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.04.037"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17f11738"},{"key":"e_1_3_3_4_1","article-title":"Oral ketamine for depression, 2: Practical considerations","volume":"80","author":"Andrade C","year":"2019","unstructured":"Andrade C (2019) Oral ketamine for depression, 2: Practical considerations. J Clin Psychiatry 80: 19f12838.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13155"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16lr11210"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.02.056"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000894"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2014.07.027"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.07.077"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.04.020"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743719828965"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004824"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620958910"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.513068"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.830301"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.04.008"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.951324"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.12.004"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.12.002"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.90"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2018.196"},{"key":"e_1_3_3_25_1","first-page":"5","article-title":"The WHODAS II: Levelling the playing field for all disorders","volume":"6","author":"Epping-Jordan JE","year":"2000","unstructured":"Epping-Jordan JE, Ustun B (2000) The WHODAS II: Levelling the playing field for all disorders. WHO Mental Health Bull 6: 5\u20136.","journal-title":"WHO Mental Health Bull"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1826-y"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0256-5"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04309"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04728"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2021.47"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.06.007"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320922474"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715002159"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.066"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0617"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.05.076"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10780.x"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25531"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jsxmed\/qdac052"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2014.922697"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.03.026"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-020-01110-5"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.02.151"},{"key":"e_1_3_3_46_1","article-title":"Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study","volume":"18","author":"Lee W","year":"2023","unstructured":"Lee W, Sheehan C, Chye R, et al. (2023) Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study. PLoS One 18: e0290876.","journal-title":"PLoS One"},{"key":"e_1_3_3_47_1","first-page":"343","article-title":"SAFTEE: A technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","unstructured":"Levine J, Schooler NR (1986) SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343\u2013381.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.08.050"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12572"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.010"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.06.050"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.07.035"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.05.088"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2023.2169349"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715001506"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80333-1"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/cotte"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1237375"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.08.019"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2012.00908.x"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22253"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.10.016"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920002187"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12475"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900625"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(86)90060-0"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.07.089"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.165498"},{"key":"e_1_3_3_76_1","unstructured":"Sciences AL (2023) atai Life Sciences announces results from Phase 2a trial of PCN-101 (R-ketamine) for treatment-resistant depression. https:\/\/www.globenewswire.com\/news-release\/2023\/01\/06\/2584334\/0\/en\/atai-Life-Sciences-Announces-Results-from-Phase-2a-Trial-of-PCN-101-R-ketamine-for-Treatment-Resistant-Depression.html"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10727"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30272-9"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16010037"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371005500303"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00317-0"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02478-9"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2359-1"},{"key":"e_1_3_3_84_1","article-title":"Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study","volume":"8","author":"Smith-Apeldoorn SY","year":"2021","unstructured":"Smith-Apeldoorn SY, Veraart JKE, Ruhe HG, et al. (2021) Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. BJPsych Open 8: e4.","journal-title":"BJPsych Open"},{"key":"e_1_3_3_85_1","volume-title":"Multidisciplinaire Richtlijn Depressie (Derde Revisie). Richtlijn Voor de Diagnostiek, Behandeling en Begeleiding Van Volwassen Pati\u00ebnten Met een Depressieve Stoornis","author":"Spijker J","year":"2013","unstructured":"Spijker J, Bockting C, Meeuwissen JAC, et al. (2013) Multidisciplinaire Richtlijn Depressie (Derde Revisie). Richtlijn Voor de Diagnostiek, Behandeling en Begeleiding Van Volwassen Pati\u00ebnten Met een Depressieve Stoornis. Utrecht: Trimbos-instituut."},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/00223891003670232"},{"key":"e_1_3_3_87_1","first-page":"45","article-title":"Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder","volume":"5","author":"Sumner RL","year":"2020","unstructured":"Sumner RL, McMillan R, Spriggs MJ, et al. (2020) Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging 5: 45\u201355.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2016.1156790"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118793104"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13260"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1097"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238135"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20r13459"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2018.51"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.165"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11731"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14318"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207927"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01577-5"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.11.033"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.02.032"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14706"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251332831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251332831","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251332831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:09Z","timestamp":1777507929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251332831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/02698811251332831"],"URL":"https:\/\/doi.org\/10.1177\/02698811251332831","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}